Browse by Medical Category
A report in Cancer Research highlights a new biomarker that may be useful in identifying patients with recurrent glioblastoma who would respond better to antiangiogenesis therapy.
The beneficial effects of anti-angiogenesis drugs in the treatment of the deadly brain tumors called glioblastomas appear to result primarily from reduction of edema – the swelling of brain tissue – and not from any direct anti-tumor effect.
report on study led by MGH investigators Greg Sorensen and Rakesh Jain
Back to Top